October 14, 2019

Dirk Oehlers
Investor Relations Officer
Tel +41 61 316 8540

Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months

• Lonza’s Ibex™ Develop will enable Genmab to support their expanding pipeline demand for product across all clinical phases and towards potential launch

• Flexible asset management designed to provide secure capacity for Genmab across their portfolio of candidates

Quote from Karen Fallen, Head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech:

“Extending this trusted relationship with Genmab is a great motivation for our teams who have been working together for a number of years. Genmab’s extensive pipeline is an opportunity for us to combine the speed and flexibility of our Ibex Solutions with the know-how needed to manufacture pioneering molecular formats.”

Basel, Switzerland – Lonza today announced an extension to its partnership with Genmab to cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline. Lonza’s Ibex Solutions in Visp (CH) is designed to provide Genmab with the flexibility and speed they need to take their candidates towards IND and commercialization.

Genmab and Lonza have a longstanding relationship, having worked together on multiple antibody-based programs since 2002.

Lonza’s Ibex Design offering enables Genmab to take their candidates from gene to IND in 12 months and then move to reserved manufacturing capacity in Ibex Develop for clinical manufacturing and BLA submission when Genmab needs it. The agreement aims to provide Genmab with security of supply and to enable Genmab to move rapidly into clinical manufacturing with the flexibility needed to manage an extensive pipeline through the demands of clinical trials.

The new agreement will cover development and clinical manufacturing of drug substance and drug product for certain programs in Genmab’s pre-clinical and clinical pipeline. These include more complex molecular formats developed using Genmab’s DuoBody® technology.

About Lonza
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma, Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at

Lonza Contact Details:
Dirk Oehlers
Investor Relations Officer
Lonza Group Ltd
Tel +41 61 316 8540

Dr. Sanna Fowler
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929

Categorized in: